A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice Weekly in Subjects With Hematologic Malignancies.

Trial Profile

A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice Weekly in Subjects With Hematologic Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs Ganetespib (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Synta Pharmaceuticals
  • Most Recent Events

    • 31 Jan 2014 According to ClinicalTrials.gov record trial status changed from active, no longer recruiting to completed.
    • 20 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 Mar 2012 Planned End Date changed from 1 Sep 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top